TherapeuticsMD Inc (NYSEMKT:TXMD) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued on Friday.

A number of other brokerages also recently weighed in on TXMD. Stifel Nicolaus restated a “buy” rating and issued a $20.00 target price on shares of TherapeuticsMD in a research note on Thursday, May 25th. Cantor Fitzgerald restated an “overweight” rating and issued a $33.00 target price on shares of TherapeuticsMD in a research note on Thursday, May 11th. Finally, Oppenheimer Holdings, Inc. upgraded TherapeuticsMD from a “market perform” rating to an “outperform” rating in a research note on Tuesday, July 11th. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $21.08.

Shares of TherapeuticsMD (TXMD) opened at 6.91 on Friday. The company’s market cap is $1.41 billion. TherapeuticsMD has a 1-year low of $3.50 and a 1-year high of $8.30. The firm has a 50-day moving average price of $5.83 and a 200 day moving average price of $5.56.

COPYRIGHT VIOLATION NOTICE: “TherapeuticsMD Inc (TXMD) Upgraded to “Buy” at BidaskClub” was first posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Analyst Recommendations for TherapeuticsMD (NYSEMKT:TXMD)

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with's FREE daily email newsletter.